A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Schizophrenia
Interventions
DRUG

Lurasidone 80mg tablet

Trial Locations (21)

19139

Quantum Clinical Services Group, Philadelphia

20016

Comprehensive NeuroScience, Inc, Washington D.C.

22044

CBH Health, L.L.C - Dominion Hospital, Falls Church

33161

Segal Institute for Clinical Research, North Miami

33301

Segal Institute for Clinical Research, Fort Lauderdale

33613

University of South Florida, Department of Psychiatry and Behavioral Medicine, Tampa

35209

Birmingham Psychiatry Pharmaceutical, Birmingham

60194

Comprehensive Neuroscience, Inc., Hoffman Estates

72211

Summit Research Group, Little Rock

75115

InSite Clinical Research, DeSoto

77401

Claghorn Lesem Research Clinic, Inc., Bellaire

78729

Community Clinical Research, Austin

78756

Future Search Trials, Austin

89102

Las Vegas

90703

Comprehensive NeuroScience, Cerritos

91786

Pacific Clinical Research, Upland

91942

Optimum Health Services, La Mesa

92123

California Clinical Trials, San Diego

92126

CA Neutopsychopharmacology Clinical Research Institute (CNRI), San Diego

92845

Collaborative Neuro Science Network, Inc., Garden Grove

08021

CNS Research Institute, Clementon

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00088621 - A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia | Biotech Hunter | Biotech Hunter